Fifty-one Stage 5 predialysis CKD patients with hemoglobin < 10 g/dL were randomly assigned to receive two period treatments with AST-120 plus once-monthly administration of continuous EPO receptor activator ( CERA , A ) and CERA alone ( B ) , with a 4-week washout period in between .